Prostate CarcinomaNCT04789018
Enhanced Genetic Awareness and Genetic Evaluation for Men Through Technology, ENGAGEMENT Study
An observational study of Prostate Carcinoma, run by Thomas Jefferson University at 1 site in United States.
Trial summary
This study assesses perceived usefulness of a web-based virtual prostate cancer genetics board for providers across academic, community, and veteran affairs settings to discuss prostate cancer genetics cases, precision treatment, and screening recommendation. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Prostate Carcinoma
- What is being tested?
- Educational Intervention, Survey Administration and Interview
- How many people
- 118 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Jan 2020to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Non-genetic providers who perform prostate cancer (PCA) genetic testing for men in their practices (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers)
Who may be able to join
- Individuals must meet one of the following inclusion criteria in order to be eligible to participate in the study:
- Healthcare providers (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers) who evaluate, manage, or treat men with prostate cancer or screen men for prostate cancer.
- Providers who perform prostate cancer genetic testing for men (genetic counselors or healthcare providers)
- Scientists and researchers
- Advocacy or patient stakeholder organization members
Who cannot join
- Non-medical providers
Trial locations and contacts
1 site in 1 country.
United States1 site
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107
About this study
Official title: Enhanced Genetic Awareness and Genetic Evaluation for Men Through Technology ENGAGEMENT Study (Virtual Genetics Board)
This study assesses perceived usefulness of a web-based virtual prostate cancer genetics board for providers across academic, community, and veteran affairs settings to discuss prostate cancer genetics cases, precision treatment, and screening recommendation. Information gained from interviews and surveys of participants taking part in the virtual genetics board may lend insights into perceived usefulness, perceived ease of use, acceptability, self-efficacy, genetics knowledge, and barriers/facilitators to implementation to refine the process.
Read the detailed description
PRIMARY OBJECTIVE:
- To assess perceived usefulness of a virtual genetics board.
SECONDARY OBJECTIVE:
- To assess acceptability/feasibility, perceived ease of use, self-efficacy for recommendations, genetics knowledge.
OUTLINE:
Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.
- Conditions
- Prostate Carcinoma
- Being tested
- Educational Intervention, Survey Administration, Interview
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Educational InterventionOther
Also called Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Attend virtual genetics board
Survey AdministrationOther
Complete survey
InterviewOther
Complete interview
| Study group | Role | What they receive |
|---|---|---|
| Observational (survey, virtual genetic board, interview) | Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board. Receives: Other: Educational Intervention; Other: Survey Administration; Other: Interview |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Likert scaled perceived usefulness scores of the virtual genetics board
Perceived usefulness will be judged against a benchmark mean score of 5/7.
Measured: After virtual genetics board
Secondary outcomes (4)
Means or changes in means of Likert scaled acceptability/feasibility
Will be summarized by means, standard deviations, and 95% confidence intervals.
Measured: Before and after virtual genetics board
Perceived ease of use
Will be summarized by means, standard deviations, and 95% confidence intervals.
Measured: After virtual genetics board
Self-efficacy for recommendations
Will be summarized by means, standard deviations, and 95% confidence intervals.
Measured: Before and after virtual genetics board
Change in mean scores on 17 genetics knowledge test questions
Will be summarized by means, standard deviations, and 95% confidence intervals.
Measured: Baseline up to post-virtual genetics board
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Mar 2021
- Study start21 Jan 2020
- Primary completion2 Jun 2022
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CarcinomaStudies of the same condition, open and under way.
- More trials run by Thomas Jefferson UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 118 participants (actual)
Sponsor and investigators
- Lead sponsor
- Thomas Jefferson University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Amy Leader, DrPH, MPH, Principal investigator, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04789018
- Sponsor's protocol ID
- 20F.936
- Other IDs
- JT 16041, 080-27000-X17501
- Status last verified
- Aug 2026
- First submitted
- 19 Feb 2021
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Enhanced Genetic Awareness and Genetic Evaluation for Men Through Technology ENGAGEMENT Study (Virtual Genetics Board)
- ClinicalTrials.gov ID
- NCT04789018
- Acronym / sponsor ID
- 20F.936
- Conditions
- Prostate Carcinoma
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 118 participants (actual)
- Lead sponsor
- Thomas Jefferson UniversityUniversity, hospital or other
- Study start
- 21 Jan 2020 (actual)
- Primary completion
- 2 Jun 2022 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 9 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study assesses perceived usefulness of a web-based virtual prostate cancer genetics board for providers across academic, community, and veteran affairs settings to discuss prostate cancer genetics cases, precision treatment, and screening recommendation. Information gained from interviews and surveys of participants taking part in the virtual genetics board may lend insights into perceived usefulness, perceived ease of use, acceptability, self-efficacy, genetics knowledge, and barriers/facilitators to implementation to refine the process.
Detailed description
PRIMARY OBJECTIVE:
- To assess perceived usefulness of a virtual genetics board.
SECONDARY OBJECTIVE:
- To assess acceptability/feasibility, perceived ease of use, self-efficacy for recommendations, genetics knowledge.
OUTLINE:
Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational (survey, virtual genetic board, interview) | – | Other: Educational Intervention, Other: Survey Administration, Other: InterviewParticipants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Non-genetic providers who perform prostate cancer (PCA) genetic testing for men in their practices (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers)
Key inclusion criteria (5 listed)
- Individuals must meet one of the following inclusion criteria in order to be eligible to participate in the study:
- Healthcare providers (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers) who evaluate, manage, or treat men with prostate cancer or screen men for prostate cancer.
- Providers who perform prostate cancer genetic testing for men (genetic counselors or healthcare providers)
- Scientists and researchers
- Advocacy or patient stakeholder organization members
Key exclusion criteria (1 listed)
- Non-medical providers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Educational InterventionAlso: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, EducationalAttend virtual genetics board | Other | Observational (survey, virtual genetic board, interview) |
| Survey AdministrationComplete survey | Other | Observational (survey, virtual genetic board, interview) |
| InterviewComplete interview | Other | Observational (survey, virtual genetic board, interview) |
Primary outcome
Mean Likert scaled perceived usefulness scores of the virtual genetics board
Time frame: After virtual genetics board
Perceived usefulness will be judged against a benchmark mean score of 5/7.
4 secondary outcomes
Means or changes in means of Likert scaled acceptability/feasibility
Time frame: Before and after virtual genetics board
Perceived ease of use
Time frame: After virtual genetics board
Self-efficacy for recommendations
Time frame: Before and after virtual genetics board
Change in mean scores on 17 genetics knowledge test questions
Time frame: Baseline up to post-virtual genetics board
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
Related trials for Prostate Carcinoma
Not yet recruitingObservational study
Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
Kidney Cancers, Prostate Cancer
Not yet recruiting
WATER IV PCa (AS Sub-study)
Localized Prostate Cancer
Recruiting
The Application of Somatosensory Interactive Pelvic Floor Muscle Training for Stress Urinary Incontinence in Men Underwent Radical Prostatectomy
Prostate Cancer (Post Prostatectomy)
RecruitingPhase 1
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
Castration Resistant Metastatic Prostate Cancer, Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Amy Leader, DrPH, MPH principal investigator
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prostate Carcinoma, run by Thomas Jefferson University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Likert scaled perceived usefulness scores of the virtual genetics board (time frame: After virtual genetics board). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.